UNRESECTABLE PARAGANGLIOMA
Clinical trials for UNRESECTABLE PARAGANGLIOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE PARAGANGLIOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE PARAGANGLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy tested as new hope for rare, Tough-to-Treat cancers
Disease control OngoingThis study tested whether the immunotherapy drug pembrolizumab could help control the growth of rare, advanced cancers that have spread or cannot be removed by surgery. It involved 157 patients with specific rare tumor types who had already tried standard treatments. The goal was…
Matched conditions: UNRESECTABLE PARAGANGLIOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
New drug combo trial offers hope for rare, Tough-to-Treat cancers
Disease control OngoingThis study is testing if adding a drug called olaparib to standard chemotherapy (temozolomide) works better to control advanced pheochromocytoma and paraganglioma. These are rare neuroendocrine tumors that have spread or cannot be removed by surgery. The trial will compare how lo…
Matched conditions: UNRESECTABLE PARAGANGLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC